| Popis: |
Studies have proposed a link between psoriasis and imbalanced gut microbiome. Therefore, the modulation of the gut microbiota with probiotics may improve clinical outcomes, chronic inflammation, and cardiovascular risk factors in patients with psoriasis.In a randomized double-blind placebo-controlled clinical trial, forty-six patients with psoriasis randomly assigned into probiotic capsules contains multi-strain at least 1.6times; 109 CFU/g bacteria or placebo for two months. Psoriasis Area and Severity Index (PASI), blood pressure, quality of life (QOL) pro-inflammatory cytokines (hs-CRP and IL1-beta;), and lipopolysaccharides (LPS) were measured.Improvements in QOL was significant in patients taking probiotics supplementation comparing to the placebo group and PASI (-5.06plusmn;2.10 vs 0.30plusmn;1.80, P=0.049) as well. After the intervention, a considerable reduction in serum LPS levels (-7.21plusmn;10.33 vs -2.74plusmn;0.97 mmol/L, P=0.010), hs-CRP levels (-1.67plusmn;0.95 vs -0.70+ 0.38 mg/L, P=0.013), and IL1-beta; levels (-1.64plusmn;1.10 vs 0.17+ -0.20 mg/L, P=0.043) in the probiotics group.This study shows that probiotics significantly improved the quality of life and seriousness in psoriatic patients. Moreover, it enhances cardiovascular risk factors and inflammatory/oxidative stress markers.This trial also was recorded in the Iranian registry of clinical trials (https://www.irct.ir) (code: IRCT20191124045483N1). J Drugs Dermatol. 2022;21(6):637-644. doi:10.36849/JDD.6237. |
